Autophagy is an evolutionarily conserved cellular programme for the turnover of organelles, proteins, and other macromolecules, involving the lysosomal degradation pathway. Emerging evidence suggests that autophagy can play a central role in human metabolism as well as impact diverse cellular processes including organelle homeostasis, cell death and proliferation, lipid and glycogen metabolism, and the regulation of inflammation and immune responses. The purpose of this review is to examine recent evidence for the role of autophagy in cellular metabolism, and its relevance to select human diseases that involve disorders of metabolism.
INTRODUCTION
Macroautophagy (abbreviated as 'autophagy') is an inducible cellular process that facilitates the degradation of cellular organelles (e.g., mitochondria, peroxisomes, ribosomes), proteins, and other macromolecular substrates (e.g., lipids, RNA, glycogen), and invading microorganisms [1, 2] . Autophagy may be nonselective, in reference to bulk degradation of cytosol, or highly selective, involving the identification (through ubiquitination), and targeting (by cargo adaptor proteins such as p62 SQSTM1 ), of specific substrates for degradation [3 Mammalian autophagy is regulated by a complex network of autophagy-related genes (ATGs) and corresponding proteins that include over 30 molecular species originally identified in yeast. The pathway is highly conserved with many corresponding mammalian homologues identified [24 && ,25]. Autophagy falls under strict regulation by nutrient and growth factor-sensitive signalling pathways, which include the mammalian target of rapamycin (mTOR), and the 5'-adenosine monophosphate (AMP)-activated protein kinase (AMPK) signalling pathways [26, 27] (Fig. 1) . Nutrient deprivation induces autophagy through inhibition of mTOR, which resides in a multiprotein complex, mTORC1. In response to stimulation by nutrients or growth factors, mTORC1 negatively regulates the ULK1/2 complex, which results in autophagy suppression [28 & ]. Depletion of cellular energy charge, as reflected by accumulation of AMP, stimulates autophagy through activation of AMPK, which regulates mTORC1 and ULK1/2 [29] .
Autophagy is also regulated by the Beclin 1 (Atg6) interactome, which associates with VPS34, a class III phosphatidylinositol-3-kinase (PI3KCIII) and other proteins (e.g., ATG14L or UVRAG; Ambra1, Rubicon). The Beclin 1 complex is negatively regulated by the Class I PI3K/Akt pathway, as well by antiapoptotic Bcl-2 family proteins. The production of phosphatidylinositol-3-phosphate (PI3P) by this complex regulates autophagosome formation [30] . Recent studies have elucidated functional links between ULK1/2 and the Beclin1 complex. Phosphorylation of Ambra1 by ULK1 releases the Beclin1 complex from cytoskeletal sequestration by dyneins, permitting the initiation of autophagy [31] . Furthermore, Ser14 phosphorylation of Beclin 1 by ULK1 enhances PI3KCIII activity [32 && ]. Autophagosome elongation is catalyzed by two ubiquitin-like conjugation systems: the Atg5-Atg12 conjugation system, and the Atg8 conjugation system. In mammals, microtubule-associated protein-1 light chain 3B (LC3B) and its related Atg8 homologues are conjugated to phosphatidylethanolamine. Subsequently, the lipid-conjugated form of LC3B (i.e., LC3B-II) is incorporated in auto-
ROLE OF AUTOPHAGY IN CELLULAR METABOLISM
By virtue of its role as a degradative process for cellular macromolecules, autophagy may play a role in cellular survival, by renewing the bioavailability of metabolic precursors during nutrient deficiency states [33] . Autophagy, which releases amino acids, lipids, and other metabolic precursors, as the result of lysosomal breakdown of complex molecules, may have a profound impact on tissue metabolism [33] . Conversely, autophagy may be upregulated by metabolic derangements that result in the accumulation of damaged or disordered macromolecules [34] . The latter may include misfolded or aggregated proteins that may accumulate in cells as a consequence of chemical or physical stress (e.g., ER stress), or as the result of mutation [35] . Furthermore, autophagy may respond to conditions that cause disruption of mitochondrial integrity and function [36 & ].
SELECTIVE AUTOPHAGY PATHWAYS
The selective targeting of distinct substrates to the autophagy pathway (termed selective autophagy) has been described for several distinct cargoes, including mitochondria (mitophagy), peroxisomes (pexophagy), ribosomes (ribophagy), and others [4 & ,24 && ]. Mitophagy is regulated by the phosphatase and tensin homolog deleted in chromosome 10 (PTEN)-induced putative kinase 1 (Pink1) and Parkinson protein-2 (Park2; Parkin) [37] . Mutations in the PINK1 and PARK2 genes are associated with recessive familial Parkinson's [38] . PINK1 is stabilized on dysfunctional mitochondria, where
KEY POINTS
Autophagy plays a central role in cellular metabolism by facilitating the turnover of organelles and proteins, clearing subcellular debris, and recycling metabolic precursors from the breakdown of complex molecules. Impaired or dysfunctional autophagy may play a pathogenic role in metabolic disorders such as diabetes, glycogen storage disorders, and myopathies.
Autophagy has a complex relationship with insulin resistance and obesity, with functional roles in adipocyte differentiation, skeletal muscle differentiation, regulation of food intake, breakdown and storage of lipid droplets, and physiological responses to exercise.
Stimulation or restoration of autophagy (e.g., with AMPK activators or gene therapy approaches), coupled with strategies to reduce inflammatory responses, may show promise in metabolic diseases such as type II diabetes.
it recruits cytosolic Parkin, an E3 ubiquitin protein ligase. Parkin catalyzes the polyubiquitination of mitochondrial outer membrane proteins, which identify depolarized mitochondria for degradation [39
&&
]. In addition to dysfunctional organelles, autophagy can degrade ubiquitinated protein aggregates, in a selective process termed 'aggrephagy'. Ubiquitinated substrates including mitochondria and protein aggregates are subsequently recognized and targeted to autophagosomes by p62 SQSTM1 and other autophagy cargo adaptor proteins [3 & ]. The p62 SQSTM1 recognizes ubiquitinated substrates through its ubiquitin-associated domain, and recognizes LC3 through its LC3-interacting region [40 & ]. ]. b-Cell-specific deletion of Atg7 resulted in mice that were hyperglycemic and glucose-intolerant, and displayed reduced b-cell mass, and decline in insulin production [42, 43] . (Upper panel) . Following fusion, the hydrolytic enzymes from the lysosomes break down the autophagosomal contents, and the remaining debris is then released for metabolic recycling. The autophagy pathway responds to various stress cues and signals from both inside and outside of the cell (Lower panel). While nutrient signals induce activity of the mammalian target of rapamycin (mTOR) signaling complex 1 (mTORC1), starvation cues directly block the activity of mTORC1. Inhibition of mTORC1 results in activation of UNC-51-like kinase 1 (ULK1), which leads to the initiating step of autophagy, whereas activation of mTORC1 inhibits the activity of ULK1, thereby preventing the onset of autophagy. The Beclin 1-interactive complex, comprised of Beclin 1, class III phosphatidylinositol-3-kinase (PIK3C3, or VPS34), and ATG14L, also regulates the autophagic pathway. This complex, when stimulated, induces the production of phosphatidylinositol-3phosphate (PI3P), leading to autophagosomal nucleation. ULK1 may also induce the activity of the Beclin 1-interactive complex, thereby enhancing the production of PI3P, which triggers the autophagosomal nucleation.
AUTOPHAGY IN DIABETES
Furthermore, Atg7-deficient b cells displayed accumulations of ubiquitinated proteins, mitochondrial dysfunction, and reduced insulin production [42, 43] . Stimulation of autophagy improved b-cell function and reduced ER stress in a model of diabetes caused by an insulin misfolding mutation [44 && ].
Recent studies indicate a potential role for autophagy in diabetic nephropathy, a condition associated with decline in kidney function, and proteinuria [45 & ]. The accumulation of cellular organelle and protein damage caused by hyperglycemia is associated with glomerular epithelial cell (podocyte) dysfunction and apoptosis. Autophagy was inhibited in podocytes by hyperglycemia in vitro, and in diabetic mice, leading to loss of epithelial barrier function [53 & ]. Chronic metformin administration conferred cardioprotection in mouse models of type I diabetes, in an AMPK-dependent manner [51, 52] . Overexpression of the stress protein heme oxygenase-1 conferred cardioprotection in the streptozotocin-induced diabetes model in mice through downregulation of cardiomyocyte apoptosis and upregulation of autophagy [54 ] . Pathogenic accumulation of glycogen may be important in several metabolic diseases including diabetic cardiomyopathy. A selective autophagydependent process termed 'glycophagy' may function in the amelioration of glycogen accumulation. Recent studies indicate that glycogen accumulation in fasting may be more prevalent in female heart tissue. The resulting induction of glycophagy was associated with cardioprotection [56 && ]. Finally, aberrant inflammatory responses, including inflammasome-associated cytokines production (e.g., interleukin-1b) may play a pathogenic role in promoting insulin-resistance and the progression of type II diabetes [57] . Our recent studies suggest that autophagy can play a key role in dampening inflammasome-associated cytokines production through stabilizing mitochondria [58] . Thus, candidate therapeutics that dampen inflammasome responses (e.g., interleukin-1b receptor antagonists), in combination with therapies that activate autophagy (e.g., the AMPK activator metformin), may have potential for the treatment of diabetes and its complications [59] .
AUTOPHAGY IN OBESITY
Genetic deletion of autophagy proteins promoted the storage of triglycerides into lipid droplets in the liver, suggesting that autophagy acts as a regulator of lipid metabolism and storage [60] . The selective autophagic degradation of lipid droplets, termed 'lipophagy' may serve to regenerate free fatty acids during nutrient deficiency states [61 & ]. Defects in this pathway may be associated with hepatic diseases, vascular diseases (atherosclerosis), obesity and metabolic syndrome, and organ dysfunction in aging [61 & ]. Hepatocyte-specific deletion of Atg7 in mice resulted in fatty liver [60] .
Autophagy was previously suggested to be downregulated in the liver in mouse models of obesity and insulin resistance. Genetic interference of Atg7 resulted in insulin resistance and promoted hepatic ER stress [62] . In contrast to these findings, the liver-specific knockout of Atg7 protected mice from diet-induced obesity and insulin resistance [63 && ]. Furthermore, skeletal muscle-specifc deletion of Atg7 resulted in lean mice that were protected against diet-induced obesity and insulin resistance. This phenotype was accompanied by increased fatty acid oxidation and browning of white adipose tissue. These changes were associated with mitochondrial dysfunction and production of fibroblast growth factor 21 (Fgf21) [63 && ]. Autophagy may play a role in adipocyte homeostasis and differentiation. Static markers of autophagy were found elevated in adipose tissue in a rat model of insulin resistance [64] . White adipose tissue-specific deletion of autophagy proteins (e.g., Atg7) resulted in lean mice with reduced white adipose tissue mass, and increased brown adipose tissue [65] . Furthermore, Atg7 deficiency in adipocytes promoted insulin sensitivity in these mice [66] . Atg7 deletion specific to Myf5þ progenitor cells impaired brown adipose differentiation, and resulted in brown adipose tissue dysfunction, as well as reduced muscle mass and glucose intolerance in mice [67 && ]. Exercise was shown to increase autophagy in cardiac and skeletal muscle, adipose tissue, and pancreatic b cells. The induction of autophagy in mice by exercise resulted in protection against glucose-intolerance caused by high-fat diet [68 & ]. Mice bearing a phospho-deficient Bcl-2 mutation were unable to induce autophagy by exercise, and lost the protective phenotype with respect to glucose tolerance [69 & ]. Recent studies indicate that stimulation of autophagy in the brain can alter the regulation of food intake. Starvation-induced autophagy led to increases in hypothalmic production of Agoutirelated peptide hormone, a regulator of food intake. Neuron-specific knockout of Atg7 resulted in a lean phenotype, and reduction of food intake in response to fasting [70] .
AUTOPHAGY IN GLYCOGEN STORAGE DISEASE
Glycogen storage disease type II (GSDII; also called Pompe disease) is an autosomal recessive disease caused by genetic deficiencies in acid a-1,4-glucosidase (GAA). Genetic deficiencies of GAA result in partial or complete inhibition of lysosomal degradation of glycogen, and consequently accumulation of glycogen-rich lysosomes, and autophagosomes [71] . The disease affects primarily skeletal and respiratory muscles, and may target vascular smooth muscle. Accumulations of autophagosomes in this disease may interfere with the function of muscle fibers [71] . Skeletal muscle biopsies from GSDII patients display accumulations of membranebound glycogen occurring in association with increased autophagic vacuoles [72 & ]. Autophagic 'flux', or lysosomal degradative activity, was impaired in both infantile and late onset GSDII patients. Accumulations of p62 SQSTM1 -containing aggregates in skeletal muscle biopsies, indicative of impaired autophagy flux, correlated with disease progression and atrophy in late-onset GSDII patients [73 && ,74]. Furthermore, autophagic flux was required for GAA maturation, and for processing of recombinant GAA [74] . Enzyme replacement therapy (ERT) for this disease is more effective at reversing the associated cardiac disease relative to skeletal muscle disease [75 & ]. The efficacy of ERT in late-onset GSDII patients was associated with restoration of autophagic flux in muscle and downregulation of atrophy-related gene expression [74] . In a murine model of Pompe disease (GAA -/mice), suppression of autophagy by muscle-specific knockout of Atg5 aggravated the muscle pathology, whereas muscle-specific knockout of Atg7 improved the efficiency of ERT in this model [76] . ]. X-linked myopathy with excessive autophagy (XMEA) is a rare myopathy caused by mutations in the VMA21 gene, an essential assembly chaperone of the vacuolar-ATPase, the principle mammalian proton pump [17] . The disease is characterized by atrophy and accumulation of autophagic vacuoles in skeletal muscle [81] . VMA21 deficiency results in incomplete lysosomal acidification, which impairs autophagic processing of substrates, and pathological accumulation of autophagosomes [82 & ].
AUTOPHAGY IN OTHER INHERITED DISORDERS
Valosin-containing protein (p97/VCP) mutations cause a group of disorders that include hereditary inclusion body myopathy, Paget's disease of bone, frontotemporal dementia; and can also contribute to the pathogenesis of familial amyotrophic lateral sclerosis. Homozygous knock-in VCP mutant mice (VCP R155H/R155H ) carrying the common R155H mutations develop muscle, heart, brain, and bone pathology, as well as evidence of autophagy and ubiquitin processing defects [83 && ]. Paget's disease is an inherited disorder of bone metabolism [84] . Mutations of the autophagy cargo adaptor p62 SQSTM1 gene, especially in the ubiquitinbinding region, have been linked to Paget's disease. p62 SQSTM1 is a multifunctional protein that regulates selective autophagy processes, but may also influence cellular signalling pathways including the nuclear factor-kB and Nrf2/Keap1-dependent signal- ]. Elevated markers of autophagy were recently reported in lung tissues from a1-AT deficiency patients with chronic lung disease [88] .
CONCLUSION
Autophagy plays a complex role in tissue homeostasis by acting as a mediator of mitochondrial homeostasis, a degradative pathway for cellular debris, and as a pathway for the recycling of metabolic precursors. Further studies are needed to understand how metabolic changes incurred by autophagy stimulation impact the progression of human diseases. Autophagy dysfunction may be an important contributor to metabolic diseases such as inherited myopathies, diabetes, obesity, and metabolic syndrome (Fig. 2) . Recent studies indicate protective functions of inducible or basal autophagy in diabetic disorders. Autophagy-stimulating drugs such as metformin, which activates the AMPK Role of autophagy in various metabolic diseases. Autophagy can be separated into different functional categories in which the targeted molecules and compounds can be linked with various metabolic diseases. Breakdown of lipid droplets (Lipophagy), protein aggregates (Aggrephagy), mitochondria (Mitophagy), and glycogen (Glycophagy) are all thought to be involved in metabolic diseases, such as obesity, myopathies, and diabetes. Defective or impaired autophagy in targeting these molecules can be an agent in inducing metabolic diseases, as improper autophagy would result in failure to break down and recycle cellular molecules. For example, obesity may be the result of defective lipophagy; diabetes and myopathies due to ineffective glycophagy and/or aggrephagy/mitophagy. Therapeutic strategies for ameliorating these metabolic disorders may include inducing autophagy via disabling the sequestration of vital autophagic proteins by inhibiting their complex formation, by gene therapy approaches, or by manipulating input signalling with pharmaceuticals.
pathway, have been proposed as potential therapies in diabetic cardiomyopathy and nephropathy. Autophagy is also proposed to play a role in lipid metabolism, adipocyte differentiation and homeostasis, regulation of food intake, and physiological responses to exercise, and thus has a complex role in obesity. Finally, the studies described in this review underscore a critical role for autophagy in the pathogenesis and therapeutic potential approaches to inherited metabolic diseases. The multifunctional nature of autophagy, as well as contrasting studies on the relative function of autophagy in these conditions, warrants additional investigation before therapeutic targeting of autophagy in human disease.
Boya P, Reggiori F, Codogno P. Emerging regulation and functions of autophagy. Nat Cell Biol 2013; 15:713-720. This is an overview on the functional significance of autophagy with emphasis on physiological significance and novel aspects. 
&&
Jin SM, Youle RJ. The accumulation of misfolded proteins in the mitochondrial matrix is sensed by PINK1 to induce PARK2/Parkin-mediated mitophagy of polarized mitochondria. Autophagy 2013; 9:1750-1757. This article demonstrates that the signal for mitophagy may involve mitochondrial protein aggregation. 40.
